Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2006-09-08 | Arlene Morris |
| 2007-03-13 | Ms. Morris brings significant expertise in the establishment of strategic partnerships, marketing and operations to MediciNova. She received her B.A. degree in Biology and Chemistry and studied marketing at Western New England College. |
| 2008-04-29 | Ms. Morris brings significant expertise in the establishment of strategic partnerships, marketing and operations to the Company. |
| 2009-04-29 | Ms. Morris was appointed President and Chief Executive Officer of Affymax, Inc., a Nasdaq-listed biotechnology company, in June 2003. She received her B.A. degree in Biology and Chemistry from Carlow College and studied marketing at Western New England College. |
| 2010-04-29 | Ms. Morris was appointed President and Chief Executive Officer of Affymax, Inc., a Nasdaq-listed biotechnology company, in June 2003. From 2001 to 2003, she served as the President and Chief Executive Officer of Clearview Projects, Inc. Prior to that, Ms. Morris served from 1996 to 2001 as the Senior Vice President, Business Development for Coulter Pharmaceutical Inc. Previously, she was the Vice President of Business Development at Scios, Inc. from 1993 to 1996, where she completed several high profile transactions, including one of the first biotech profit-sharing deals for a late-stage product. From 1977 through 1993, Ms. Morris held various management and executive positions at Johnson & Johnson in sales, marketing, new product development and business development, holding the position of Vice President of Business Development for McNeil Pharmaceutical from 1988 to 1993. She received her B.A. degree in Biology and Chemistry from Carlow College and studied marketing at Western New England College. |
| 2011-04-29 | She received her B.A. degree in Biology and Chemistry from Carlow College and studied marketing at Western New England College. |
| 2012-04-30 | Ms. Morris brings significant expertise in the establishment of strategic partnerships, marketing and operations to us. Ms. Morris is currently CEO of Syndax Pharmaceuticals a late-stage clinical development oncology company with a platform based on an epigenetic approach to overcoming the problem of resistance in cancer therapy. |
| 2013-04-29 | She received her B.A. degree in Biology and Chemistry from Carlow College and studied marketing at Western New England College. |
Data sourced from SEC filings. Last updated: 2026-02-03